nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADORA2A—NGF-independant TRKA activation—NTRK2—peripheral nervous system neoplasm	0.0254	0.117	CbGpPWpGaD
Vidarabine—ADORA2A—Activation of TRKA receptors—NTRK2—peripheral nervous system neoplasm	0.022	0.101	CbGpPWpGaD
Vidarabine—ADORA2A—NGF-independant TRKA activation—NTRK1—peripheral nervous system neoplasm	0.0207	0.0953	CbGpPWpGaD
Vidarabine—ADORA2A—Activation of TRKA receptors—NTRK1—peripheral nervous system neoplasm	0.0179	0.0824	CbGpPWpGaD
Vidarabine—Tenofovir—NME1—peripheral nervous system neoplasm	0.0177	0.642	CrCbGaD
Vidarabine—ADORA2A—GPCRs, Other—ADGRV1—peripheral nervous system neoplasm	0.0151	0.0694	CbGpPWpGaD
Vidarabine—ADK—Nucleotide metabolism—NME1—peripheral nervous system neoplasm	0.0132	0.0607	CbGpPWpGaD
Vidarabine—ADA—Nucleotide metabolism—NME1—peripheral nervous system neoplasm	0.00898	0.0413	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CD34—peripheral nervous system neoplasm	0.00641	0.0295	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—BCHE—peripheral nervous system neoplasm	0.00537	0.0247	CbGpPWpGaD
Vidarabine—ADORA2A—Monoamine Transport—TH—peripheral nervous system neoplasm	0.00528	0.0243	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—ALK—peripheral nervous system neoplasm	0.00517	0.187	CrCbGaD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.0051	0.0235	CbGpPWpGaD
Vidarabine—Adenosine triphosphate—AKT1—peripheral nervous system neoplasm	0.00404	0.146	CrCbGaD
Vidarabine—ADA—p73 transcription factor network—NTRK1—peripheral nervous system neoplasm	0.00397	0.0182	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—peripheral nervous system neoplasm	0.00317	0.0146	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—peripheral nervous system neoplasm	0.00284	0.013	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.00281	0.0129	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00256	0.0118	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.00211	0.00971	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.00199	0.00915	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.00188	0.00864	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00177	0.00813	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00174	0.008	CbGpPWpGaD
Vidarabine—ADK—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00173	0.00795	CbGpPWpGaD
Vidarabine—ADORA2A—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.00146	0.0067	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—NRAS—peripheral nervous system neoplasm	0.00145	0.00666	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—MYC—peripheral nervous system neoplasm	0.00142	0.00651	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—MYC—peripheral nervous system neoplasm	0.00135	0.0062	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00135	0.00619	CbGpPWpGaD
Vidarabine—Tremor—Alitretinoin—peripheral nervous system neoplasm	0.00133	0.00177	CcSEcCtD
Vidarabine—Back pain—Vincristine—peripheral nervous system neoplasm	0.00133	0.00176	CcSEcCtD
Vidarabine—Pain—Topotecan—peripheral nervous system neoplasm	0.00132	0.00175	CcSEcCtD
Vidarabine—Ventricular tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.00132	0.00175	CcSEcCtD
Vidarabine—Pain—Isotretinoin—peripheral nervous system neoplasm	0.00131	0.00174	CcSEcCtD
Vidarabine—Pain—Tretinoin—peripheral nervous system neoplasm	0.00131	0.00174	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—peripheral nervous system neoplasm	0.00131	0.00174	CcSEcCtD
Vidarabine—Agitation—Alitretinoin—peripheral nervous system neoplasm	0.00131	0.00173	CcSEcCtD
Vidarabine—Tinnitus—Cisplatin—peripheral nervous system neoplasm	0.0013	0.00172	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NTRK2—peripheral nervous system neoplasm	0.0013	0.00597	CbGpPWpGaD
Vidarabine—Pain—Melphalan—peripheral nervous system neoplasm	0.00129	0.00172	CcSEcCtD
Vidarabine—Flushing—Cisplatin—peripheral nervous system neoplasm	0.00129	0.00171	CcSEcCtD
Vidarabine—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.00129	0.00171	CcSEcCtD
Vidarabine—Discomfort—Dactinomycin—peripheral nervous system neoplasm	0.00129	0.00171	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00129	0.00594	CbGpPWpGaD
Vidarabine—Syncope—Alitretinoin—peripheral nervous system neoplasm	0.00128	0.00169	CcSEcCtD
Vidarabine—Hypoaesthesia—Etoposide—peripheral nervous system neoplasm	0.00127	0.00168	CcSEcCtD
Vidarabine—Agitation—Vincristine—peripheral nervous system neoplasm	0.00126	0.00167	CcSEcCtD
Vidarabine—Palpitations—Alitretinoin—peripheral nervous system neoplasm	0.00126	0.00167	CcSEcCtD
Vidarabine—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.00126	0.00166	CcSEcCtD
Vidarabine—Loss of consciousness—Alitretinoin—peripheral nervous system neoplasm	0.00125	0.00166	CcSEcCtD
Vidarabine—ADK—Metabolism—GNS—peripheral nervous system neoplasm	0.00125	0.00575	CbGpPWpGaD
Vidarabine—Arrhythmia—Cisplatin—peripheral nervous system neoplasm	0.00125	0.00165	CcSEcCtD
Vidarabine—Cough—Alitretinoin—peripheral nervous system neoplasm	0.00124	0.00165	CcSEcCtD
Vidarabine—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.00123	0.00164	CcSEcCtD
Vidarabine—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.00123	0.00163	CcSEcCtD
Vidarabine—Urticaria—Topotecan—peripheral nervous system neoplasm	0.00123	0.00163	CcSEcCtD
Vidarabine—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.00122	0.00161	CcSEcCtD
Vidarabine—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.00122	0.00161	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.00121	0.00558	CbGpPWpGaD
Vidarabine—Chest pain—Alitretinoin—peripheral nervous system neoplasm	0.00121	0.00161	CcSEcCtD
Vidarabine—Anxiety—Alitretinoin—peripheral nervous system neoplasm	0.00121	0.0016	CcSEcCtD
Vidarabine—Urticaria—Melphalan—peripheral nervous system neoplasm	0.0012	0.00159	CcSEcCtD
Vidarabine—ADK—Metabolism—NME1—peripheral nervous system neoplasm	0.0012	0.00551	CbGpPWpGaD
Vidarabine—Discomfort—Alitretinoin—peripheral nervous system neoplasm	0.0012	0.00159	CcSEcCtD
Vidarabine—Convulsion—Vincristine—peripheral nervous system neoplasm	0.00119	0.00158	CcSEcCtD
Vidarabine—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.00119	0.00157	CcSEcCtD
Vidarabine—Flushing—Etoposide—peripheral nervous system neoplasm	0.00119	0.00157	CcSEcCtD
Vidarabine—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.00119	0.00157	CcSEcCtD
Vidarabine—Hypertension—Vincristine—peripheral nervous system neoplasm	0.00119	0.00157	CcSEcCtD
Vidarabine—ADA—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00118	0.00541	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.00116	0.00154	CcSEcCtD
Vidarabine—ADK—Metabolism—COX2—peripheral nervous system neoplasm	0.00116	0.00531	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.00115	0.00153	CcSEcCtD
Vidarabine—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.00114	0.00152	CcSEcCtD
Vidarabine—Shock—Alitretinoin—peripheral nervous system neoplasm	0.00114	0.00152	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.00114	0.00151	CcSEcCtD
Vidarabine—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.00114	0.00151	CcSEcCtD
Vidarabine—Tremor—Cisplatin—peripheral nervous system neoplasm	0.00114	0.00151	CcSEcCtD
Vidarabine—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.00113	0.0015	CcSEcCtD
Vidarabine—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.00113	0.0015	CcSEcCtD
Vidarabine—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.00113	0.0015	CcSEcCtD
Vidarabine—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.00112	0.00149	CcSEcCtD
Vidarabine—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.00112	0.00148	CcSEcCtD
Vidarabine—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.00112	0.00148	CcSEcCtD
Vidarabine—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00111	0.00147	CcSEcCtD
Vidarabine—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.0011	0.00146	CcSEcCtD
Vidarabine—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.0011	0.00146	CcSEcCtD
Vidarabine—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.00109	0.00144	CcSEcCtD
Vidarabine—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00109	0.00144	CcSEcCtD
Vidarabine—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.00109	0.00144	CcSEcCtD
Vidarabine—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.00108	0.00143	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.00108	0.00496	CbGpPWpGaD
Vidarabine—Back pain—Etoposide—peripheral nervous system neoplasm	0.00108	0.00143	CcSEcCtD
Vidarabine—Pain—Dactinomycin—peripheral nervous system neoplasm	0.00107	0.00142	CcSEcCtD
Vidarabine—Cardiac failure—Epirubicin—peripheral nervous system neoplasm	0.00106	0.00141	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—HRAS—peripheral nervous system neoplasm	0.00106	0.00487	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NTRK1—peripheral nervous system neoplasm	0.00106	0.00487	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.00106	0.0014	CcSEcCtD
Vidarabine—Cerebrovascular accident—Epirubicin—peripheral nervous system neoplasm	0.00106	0.0014	CcSEcCtD
Vidarabine—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.00105	0.00139	CcSEcCtD
Vidarabine—Hypotension—Vincristine—peripheral nervous system neoplasm	0.00105	0.00139	CcSEcCtD
Vidarabine—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.00104	0.00138	CcSEcCtD
Vidarabine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.00104	0.00137	CcSEcCtD
Vidarabine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.00103	0.00137	CcSEcCtD
Vidarabine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.00103	0.00136	CcSEcCtD
Vidarabine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00102	0.00135	CcSEcCtD
Vidarabine—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.00102	0.00135	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.00102	0.00135	CcSEcCtD
Vidarabine—Affect lability—Epirubicin—peripheral nervous system neoplasm	0.00102	0.00135	CcSEcCtD
Vidarabine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00101	0.00134	CcSEcCtD
Vidarabine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00101	0.00134	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—BCHE—peripheral nervous system neoplasm	0.00101	0.00466	CbGpPWpGaD
Vidarabine—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.00101	0.00133	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—NTRK2—peripheral nervous system neoplasm	0.000999	0.00459	CbGpPWpGaD
Vidarabine—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000994	0.00132	CcSEcCtD
Vidarabine—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000991	0.00131	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—peripheral nervous system neoplasm	0.000984	0.0013	CcSEcCtD
Vidarabine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000983	0.0013	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—peripheral nervous system neoplasm	0.000981	0.0013	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—peripheral nervous system neoplasm	0.00098	0.0013	CcSEcCtD
Vidarabine—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000977	0.00129	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000977	0.00129	CcSEcCtD
Vidarabine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000975	0.00129	CcSEcCtD
Vidarabine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000975	0.00129	CcSEcCtD
Vidarabine—Rash—Topotecan—peripheral nervous system neoplasm	0.000975	0.00129	CcSEcCtD
Vidarabine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000974	0.00129	CcSEcCtD
Vidarabine—Cough—Etoposide—peripheral nervous system neoplasm	0.00097	0.00129	CcSEcCtD
Vidarabine—Headache—Topotecan—peripheral nervous system neoplasm	0.000969	0.00128	CcSEcCtD
Vidarabine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000967	0.00128	CcSEcCtD
Vidarabine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000967	0.00128	CcSEcCtD
Vidarabine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000967	0.00128	CcSEcCtD
Vidarabine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000966	0.00128	CcSEcCtD
Vidarabine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000966	0.00128	CcSEcCtD
Vidarabine—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000963	0.00128	CcSEcCtD
Vidarabine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000963	0.00128	CcSEcCtD
Vidarabine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000961	0.00127	CcSEcCtD
Vidarabine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000961	0.00127	CcSEcCtD
Vidarabine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.00096	0.00127	CcSEcCtD
Vidarabine—Pain—Vincristine—peripheral nervous system neoplasm	0.000958	0.00127	CcSEcCtD
Vidarabine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000958	0.00127	CcSEcCtD
Vidarabine—Rash—Melphalan—peripheral nervous system neoplasm	0.000955	0.00126	CcSEcCtD
Vidarabine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000954	0.00126	CcSEcCtD
Vidarabine—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000947	0.00125	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—peripheral nervous system neoplasm	0.000943	0.00125	CcSEcCtD
Vidarabine—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000935	0.00124	CcSEcCtD
Vidarabine—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000926	0.00123	CcSEcCtD
Vidarabine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000924	0.00122	CcSEcCtD
Vidarabine—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000924	0.00122	CcSEcCtD
Vidarabine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000918	0.00122	CcSEcCtD
Vidarabine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000911	0.00121	CcSEcCtD
Vidarabine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000911	0.00121	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	0.000911	0.00121	CcSEcCtD
Vidarabine—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000907	0.0012	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—peripheral nervous system neoplasm	0.000907	0.0012	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000902	0.0012	CcSEcCtD
Vidarabine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.0009	0.00119	CcSEcCtD
Vidarabine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000899	0.00119	CcSEcCtD
Vidarabine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000889	0.00118	CcSEcCtD
Vidarabine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000886	0.00117	CcSEcCtD
Vidarabine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000883	0.00117	CcSEcCtD
Vidarabine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000877	0.00116	CcSEcCtD
Vidarabine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000856	0.00113	CcSEcCtD
Vidarabine—ADA—Metabolism—GNS—peripheral nervous system neoplasm	0.000851	0.00391	CbGpPWpGaD
Vidarabine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000848	0.00112	CcSEcCtD
Vidarabine—Pain—Cisplatin—peripheral nervous system neoplasm	0.000847	0.00112	CcSEcCtD
Vidarabine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000834	0.00111	CcSEcCtD
Vidarabine—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000826	0.00109	CcSEcCtD
Vidarabine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000825	0.00109	CcSEcCtD
Vidarabine—ADA—Metabolism—NME1—peripheral nervous system neoplasm	0.000816	0.00375	CbGpPWpGaD
Vidarabine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000815	0.00108	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—NTRK1—peripheral nervous system neoplasm	0.000815	0.00374	CbGpPWpGaD
Vidarabine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000809	0.00107	CcSEcCtD
Vidarabine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000807	0.00107	CcSEcCtD
Vidarabine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000804	0.00106	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000798	0.00106	CcSEcCtD
Vidarabine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000797	0.00106	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000795	0.00365	CbGpPWpGaD
Vidarabine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000791	0.00105	CcSEcCtD
Vidarabine—ADA—Metabolism—COX2—peripheral nervous system neoplasm	0.000785	0.00361	CbGpPWpGaD
Vidarabine—Pain—Etoposide—peripheral nervous system neoplasm	0.000776	0.00103	CcSEcCtD
Vidarabine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000769	0.00102	CcSEcCtD
Vidarabine—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000765	0.00101	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000765	0.00101	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000762	0.0035	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ENO2—peripheral nervous system neoplasm	0.000758	0.00348	CbGpPWpGaD
Vidarabine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000745	0.000987	CcSEcCtD
Vidarabine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000741	0.000982	CcSEcCtD
Vidarabine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000739	0.000979	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000738	0.000978	CcSEcCtD
Vidarabine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000733	0.000971	CcSEcCtD
Vidarabine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000732	0.00097	CcSEcCtD
Vidarabine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.00073	0.000967	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000729	0.000966	CcSEcCtD
Vidarabine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000728	0.000965	CcSEcCtD
Vidarabine—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000721	0.000955	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000712	0.000944	CcSEcCtD
Vidarabine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000712	0.000944	CcSEcCtD
Vidarabine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000711	0.000942	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000707	0.000937	CcSEcCtD
Vidarabine—Rash—Vincristine—peripheral nervous system neoplasm	0.000706	0.000936	CcSEcCtD
Vidarabine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000706	0.000935	CcSEcCtD
Vidarabine—Adenosine triphosphate—ABCB1—peripheral nervous system neoplasm	0.000705	0.0255	CrCbGaD
Vidarabine—Headache—Vincristine—peripheral nervous system neoplasm	0.000702	0.00093	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000692	0.00318	CbGpPWpGaD
Vidarabine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000691	0.000915	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000675	0.0031	CbGpPWpGaD
Vidarabine—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000674	0.000894	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000669	0.000886	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000668	0.000885	CcSEcCtD
Vidarabine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000665	0.000882	CcSEcCtD
Vidarabine—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000664	0.00088	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000664	0.00088	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000663	0.00305	CbGpPWpGaD
Vidarabine—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000659	0.000873	CcSEcCtD
Vidarabine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000651	0.000863	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000645	0.000855	CcSEcCtD
Vidarabine—ADK—Metabolism—BCHE—peripheral nervous system neoplasm	0.000641	0.00294	CbGpPWpGaD
Vidarabine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.00064	0.000847	CcSEcCtD
Vidarabine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00063	0.000834	CcSEcCtD
Vidarabine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000625	0.000828	CcSEcCtD
Vidarabine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000624	0.000827	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000618	0.000818	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000615	0.000815	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000615	0.000815	CcSEcCtD
Vidarabine—Tension—Epirubicin—peripheral nervous system neoplasm	0.000612	0.00081	CcSEcCtD
Vidarabine—ADK—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000611	0.00281	CbGpPWpGaD
Vidarabine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.00061	0.000809	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000606	0.00278	CbGpPWpGaD
Vidarabine—Nervousness—Epirubicin—peripheral nervous system neoplasm	0.000605	0.000802	CcSEcCtD
Vidarabine—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000603	0.000799	CcSEcCtD
Vidarabine—ADK—Metabolism—TH—peripheral nervous system neoplasm	0.000602	0.00277	CbGpPWpGaD
Vidarabine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.0006	0.000795	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000597	0.000791	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000592	0.000784	CcSEcCtD
Vidarabine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000588	0.00078	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000587	0.000778	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000577	0.00265	CbGpPWpGaD
Vidarabine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000577	0.000765	CcSEcCtD
Vidarabine—Agitation—Epirubicin—peripheral nervous system neoplasm	0.000573	0.000759	CcSEcCtD
Vidarabine—Rash—Etoposide—peripheral nervous system neoplasm	0.000572	0.000758	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000572	0.000757	CcSEcCtD
Vidarabine—Headache—Etoposide—peripheral nervous system neoplasm	0.000568	0.000753	CcSEcCtD
Vidarabine—Tension—Doxorubicin—peripheral nervous system neoplasm	0.000566	0.00075	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000565	0.000748	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	0.00056	0.000742	CcSEcCtD
Vidarabine—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000559	0.000741	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000558	0.000739	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000552	0.00253	CbGpPWpGaD
Vidarabine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000551	0.00073	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000548	0.000726	CcSEcCtD
Vidarabine—Cough—Epirubicin—peripheral nervous system neoplasm	0.000544	0.000721	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000543	0.00072	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.00054	0.000716	CcSEcCtD
Vidarabine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000539	0.000714	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000538	0.000713	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	0.000534	0.00245	CbGpPWpGaD
Vidarabine—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000531	0.000703	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—peripheral nervous system neoplasm	0.00053	0.000702	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.00053	0.00243	CbGpPWpGaD
Vidarabine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000529	0.000701	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000524	0.000695	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000524	0.00241	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	0.000519	0.00239	CbGpPWpGaD
Vidarabine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000519	0.000688	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000517	0.000685	CcSEcCtD
Vidarabine—ADA—Metabolism—ENO2—peripheral nervous system neoplasm	0.000515	0.00237	CbGpPWpGaD
Vidarabine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.00051	0.000675	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000509	0.000674	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000507	0.000672	CcSEcCtD
Vidarabine—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000503	0.000667	CcSEcCtD
Vidarabine—Shock—Epirubicin—peripheral nervous system neoplasm	0.0005	0.000663	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.0005	0.000662	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000498	0.00066	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000496	0.000658	CcSEcCtD
Vidarabine—ADK—Metabolism—GNAS—peripheral nervous system neoplasm	0.000492	0.00226	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000492	0.000652	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000491	0.000651	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000489	0.000648	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000485	0.000643	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000484	0.00222	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000483	0.00222	CbGpPWpGaD
Vidarabine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.00048	0.000636	CcSEcCtD
Vidarabine—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000475	0.00063	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000471	0.000624	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000463	0.000614	CcSEcCtD
Vidarabine—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000463	0.000614	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000459	0.000609	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000457	0.000605	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000455	0.000603	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000453	0.000601	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000452	0.000599	CcSEcCtD
Vidarabine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.00044	0.000583	CcSEcCtD
Vidarabine—ADA—Metabolism—BCHE—peripheral nervous system neoplasm	0.000436	0.002	CbGpPWpGaD
Vidarabine—Pain—Epirubicin—peripheral nervous system neoplasm	0.000435	0.000576	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000429	0.000568	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000423	0.00056	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.00042	0.000556	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000418	0.000554	CcSEcCtD
Vidarabine—ADA—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000415	0.00191	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.000411	0.00189	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TH—peripheral nervous system neoplasm	0.000409	0.00188	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000409	0.00188	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	0.000406	0.00187	CbGpPWpGaD
Vidarabine—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000404	0.000535	CcSEcCtD
Vidarabine—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000402	0.000533	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000392	0.0018	CbGpPWpGaD
Vidarabine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000375	0.000497	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000374	0.000495	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—peripheral nervous system neoplasm	0.000373	0.00171	CbGpPWpGaD
Vidarabine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000365	0.000484	CcSEcCtD
Vidarabine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000459	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000342	0.00157	CbGpPWpGaD
Vidarabine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000338	0.000447	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000336	0.000446	CcSEcCtD
Vidarabine—ADA—Metabolism—GNAS—peripheral nervous system neoplasm	0.000334	0.00154	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000328	0.00151	CbGpPWpGaD
Vidarabine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000323	0.000429	CcSEcCtD
Vidarabine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000321	0.000425	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.00032	0.000425	CcSEcCtD
Vidarabine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000319	0.000422	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000317	0.00146	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—NRAS—peripheral nervous system neoplasm	0.000312	0.00143	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000311	0.000412	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000311	0.00143	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00031	0.00142	CbGpPWpGaD
Vidarabine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000302	0.0004	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000299	0.00137	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.000397	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	0.000297	0.00136	CbGpPWpGaD
Vidarabine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000297	0.000393	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000296	0.000393	CcSEcCtD
Vidarabine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000295	0.000391	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000286	0.00131	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.00037	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000272	0.00125	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	0.000262	0.00121	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—peripheral nervous system neoplasm	0.000228	0.00105	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000215	0.000986	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—peripheral nervous system neoplasm	0.000202	0.000927	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000189	0.000868	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000184	0.000843	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000175	0.000804	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000161	0.000738	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—peripheral nervous system neoplasm	0.000133	0.00061	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000114	0.000522	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000112	0.000513	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—peripheral nervous system neoplasm	9.02e-05	0.000415	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	8.82e-05	0.000405	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	8.31e-05	0.000382	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	8.08e-05	0.000371	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	8e-05	0.000368	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	7.34e-05	0.000337	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.71e-05	0.000308	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	6.25e-05	0.000287	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.13e-05	0.000236	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.91e-05	0.000225	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	4.33e-05	0.000199	CbGpPWpGaD
